Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.

Taeho Greg Rhee, Pasha A Davoudian, Gerard Sanacora, Samuel T Wilkinson

Journal: Drug discovery today 2023;28(12):103818

PMID: 37925136

Full Text on Elsevier Science View on PubMed

Abstract

Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential interactive effects these compounds can have with psychotherapeutic approaches. We provide a cutting-edge review of active and recently completed clinical trials based on the published literature (from MEDLINE), published abstracts at citable conferences, clinical trials from the US Clinical Trials registry (clinicaltrials.gov) and media press releases.

Address: Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.; Medical Scientist Training Program, Yale School of Medicine, New Haven, CT, USA; Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, CT, USA.; Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.; Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. Electronic address: [email protected].

DOI: 10.1016/j.drudis.2023.103818

Link outs

Free resources

Medical:

https://medlineplus.gov/mentaldisorders.html

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1359...

MeSH Terms: Humans, Hallucinogens, Lysergic Acid Diethylamide, Mental Disorders, Psilocybin, N,N-Dimethyltryptamine